- Home
- UWMC vs AUPH Comparison
UWMC vs AUPH Comparison
Compare UWMC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | AUPH |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Canada |
| Employees | 9100 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.9B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | UWMC | AUPH |
|---|---|---|
| Price | $3.45 | $14.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $6.66 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 17.2M | 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.33% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $1.60 | $16.53 |
| Revenue Next Year | $15.00 | $16.24 |
| P/E Ratio | $82.22 | ★ $7.06 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $3.38 | $6.83 |
| 52 Week High | $7.14 | $16.54 |
Technical Indicators
Market Signals| Indicator | UWMC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 30.54 | 48.71 |
| Support Level | N/A | $13.52 |
| Resistance Level | $5.99 | $15.23 |
| Average True Range (ATR) | 0.19 | 0.46 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 4.18 | 33.82 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.